Access Pharmaceuticals, Inc. (OTC BB: ACCP), an emerging biopharmaceutical company, is committed to the development and commercialization of propriety products for the treatment and supportive care of cancer patients. Access’ products currently include ProLindac(TM), the company’s lead oncology drug which is currently in Phase 2 clinical testing; and MuGard(TM), a viscous, mucoadhesive rinse for the management of patients with mucositis. For further information, visit the Company’s web site at www.accesspharma.com.
- 18 years ago
QualityStocks
Access Pharmaceuticals, Inc. (OTC BB: ACCP)
Tags Rodman & Renshaw
Related Post
-
Quantum BioPharma Ltd. (NASDAQ: QNTM) Pursues a New Path for Better Multiple Sclerosis Treatments
In the United States alone, close to one million people are living with MS, with…
-
Why Verbal Skills Aren’t Enough: WRAP’s New Doctrine Aims to Give Officers a Lawful Next Step
California's SB 230 requires agencies to incorporate de-escalation and alternatives to force into their use-of-force…
-
Beeline Holdings Inc. (NASDAQ: BLNE) Partners with Loft 100 Studios to Examine the Mortgage Market and New Approaches to Homeownership
The partnership will focus on the production of a 45-minute “Bizumentary” examining current challenges and…